Individualized #cancer #vaccines targeting #neoantigens have shown promise in small-scale studies, but the field is waiting on data from Merck's & Moderna's phase 3 trial of the #mRNA vaccine Intismeran autogene in #melanoma. Just out in @natbiotech.nature.com
www.nature.com/articles/s41...
nature.com
Individualized mRNA cancer vaccines make strides - Nature Biotechnology
The first cancer vaccines matched to a person’s unique tumor neoantigens are forging ahead, with expectations running high as the field awaits results from the first pivotal trial.